MAP2K7 and melanoma: Cells were treated with varying doses of the current standard of care for mutant BRaf V600E melanoma patients [20], a combination of Dabrafenib (Dab), a BRaf V600E inhibitor, and Trametinib (Tram), a pan MEK inhibitor, a drug combination which we abbreviate as RMIC.